At1g51810 Antibody

What is the At1g51810 Antibody and what protein does it target?

The At1g51810 Antibody (product code CSB-PA867045XA01DOA) is a research reagent designed to target the protein encoded by the At1g51810 gene in Arabidopsis thaliana (Mouse-ear cress), which corresponds to UniProt accession number Q9FZB8 . This antibody is specifically designed for detecting the native protein in experimental systems and is typically available in research quantities (2ml/0.1ml) for laboratory use .

What experimental applications is the At1g51810 Antibody validated for?

The At1g51810 Antibody is commonly employed in multiple molecular and cellular detection methods. While specific validation data for this antibody wasn't provided in the search results, plant antibodies generally undergo validation for Western blotting, immunohistochemistry (IHC), immunocytochemistry (ICC), and immunoprecipitation (IP) applications. Researchers should verify application-specific validation with the manufacturer before designing experiments, as antibodies may perform differently across various experimental conditions .

How can I rigorously validate the specificity of the At1g51810 Antibody?

Validating antibody specificity is crucial for meaningful results. Based on established validation protocols, researchers should:

• Perform knockout control experiments: Test the antibody against tissues or lysates from At1g51810 knockout mutants, which should show no signal if the antibody is specific .

• Conduct side-by-side comparisons: Use multiple antibodies targeting the same protein but with different epitopes to verify consistent staining patterns .

• Correlate with RNA expression data: Evaluate if protein detection patterns correlate with RNA expression profiles of At1g51810 in different tissues .

• Preabsorption tests: Pre-incubate the antibody with purified target antigen before staining to confirm signal reduction .

The following validation criteria table adapted from enhanced validation protocols can guide your assessment:

Following these validation steps is essential as research has revealed that many commercial antibodies demonstrate insufficient specificity, leading to misidentification of target proteins .

What positive and negative controls should I implement when using At1g51810 Antibody?

For rigorous experimental design, incorporate the following controls:

Positive controls:

• Wild-type Arabidopsis thaliana tissues known to express At1g51810 based on transcriptomic data

• Recombinant At1g51810 protein (if available)

• Overexpression systems where At1g51810 is artificially expressed

Negative controls:

• At1g51810 knockout or knockdown plant tissues

• Tissues known not to express the target protein

• Secondary antibody-only controls to assess background staining

• Isotype controls to evaluate non-specific binding

Implementing these controls is particularly important given documented cases where antibodies produce identical band patterns in both wild-type and knockout tissues, indicating potential cross-reactivity with unintended targets .

What are the optimal sample preparation methods for Western blotting with At1g51810 Antibody?

For optimal Western blot results with plant proteins like At1g51810:

• Sample extraction:

  • Use a buffer containing 50mM Tris-HCl (pH 7.5), 150mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, and protease inhibitor cocktail

  • Consider adding phosphatase inhibitors if studying phosphorylation states

  • Include 5-10mM DTT or β-mercaptoethanol to reduce disulfide bonds

• Protein separation:

  • Load 20-50μg of total protein per lane

  • Use 10-12% SDS-PAGE gels for optimal separation around the expected molecular weight

  • Transfer to PVDF membranes (preferred for plant proteins over nitrocellulose)

• Blocking and detection:

  • Block with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

  • Incubate with primary antibody (1:500-1:2000 dilution range, optimized empirically)

  • Wash thoroughly with TBST (4 × 5 minutes)

  • Use appropriate HRP-conjugated secondary antibody

This methodology addresses concerns regarding false positive identification, which has been documented with multiple antibodies in the literature .

How should I optimize immunohistochemistry protocols for detecting At1g51810 in plant tissues?

For plant tissue immunohistochemistry with At1g51810 Antibody:

• Tissue fixation and processing:

  • Fix tissues in 4% paraformaldehyde for 12-24 hours

  • Perform gradual dehydration through ethanol series (30%, 50%, 70%, 85%, 95%, 100%)

  • Clear with xylene and embed in paraffin

  • Section at 5-8μm thickness

• Antigen retrieval:

  • Heat-induced epitope retrieval in 10mM sodium citrate buffer (pH 6.0)

  • Maintain at 95-98°C for 20-30 minutes, then cool gradually

• Staining protocol:

  • Block endogenous peroxidases with 3% H₂O₂ in methanol

  • Block non-specific binding with 5% normal serum in PBS with 0.1% Triton X-100

  • Apply primary antibody (1:100-1:500 dilution) overnight at 4°C

  • Use appropriate detection system (HRP/DAB or fluorescent secondary antibodies)

This protocol minimizes non-specific binding while maximizing target detection, addressing specificity concerns raised in antibody validation studies .

How can orthogonal methods complement At1g51810 Antibody studies to ensure reliable protein identification?

To enhance confidence in At1g51810 detection and address potential antibody specificity issues, implement these orthogonal approaches:

• Mass spectrometry validation:

  • Perform immunoprecipitation with At1g51810 Antibody

  • Analyze precipitated proteins by LC-MS/MS

  • Confirm presence of target peptides matching At1g51810 sequence

• Genetic approaches:

  • Create tagged versions of At1g51810 (GFP, FLAG, HA)

  • Compare localization and expression patterns with antibody staining

  • Use CRISPR/Cas9 to generate knockout lines as definitive negative controls

• Transcriptomics correlation:

  • Compare protein detection patterns with RNA-seq or qRT-PCR data

  • Calculate RNA similarity scores to evaluate consistency between protein and transcript levels

  • Address discrepancies through protein stability or post-transcriptional regulation analyses

This multi-method validation approach aligns with enhanced validation protocols that have successfully identified previously undetected "missing proteins" and is particularly important given documented cases of antibody cross-reactivity .

What strategies can mitigate cross-reactivity concerns when using At1g51810 Antibody?

To address potential cross-reactivity with other Arabidopsis proteins:

• Epitope mapping and analysis:

  • Identify the specific epitope recognized by the antibody

  • Perform BLAST analyses to identify similar sequences in the Arabidopsis proteome

  • Test antibody against predicted cross-reactive proteins

• Competitive binding assays:

  • Pre-incubate antibody with excess purified target peptide

  • Observe signal reduction in subsequent applications

  • Quantify degree of signal blocking to assess specificity

• Immunodepletion experiments:

  • Serially deplete antibody with recombinant target protein

  • Test residual binding capacity against tissue samples

  • Measure reduction in specific vs. non-specific signals

These approaches directly address the concerning finding that many commercial antibodies produce identical band patterns in both wild-type and knockout tissues, indicating target-independent binding to unknown proteins .

How should I interpret inconsistent results between At1g51810 Antibody detection and transcript expression data?

When protein detection and transcript levels show discordance:

• Systematic evaluation framework:

  • Categorize discrepancies as "protein detected/low transcript" or "transcript detected/low protein"

  • Assess temporal dynamics by sampling across multiple timepoints

  • Consider tissue-specific post-transcriptional regulation

• Biological explanations to investigate:

  • Protein stability and half-life differences

  • Post-translational modifications affecting epitope recognition

  • Subcellular localization restricting antibody accessibility

  • RNA regulation mechanisms (miRNA targeting, translation efficiency)

• Technical considerations:

  • Evaluate RNA similarity scores as defined in validation frameworks

  • Assess if discrepancies fall into "low consistency" or "very low consistency" categories

  • Implement additional validation steps for uncertain correlations

This approach recognizes that protein-RNA discrepancies may reflect actual biological regulation rather than technical artifacts, though antibody specificity issues should always be considered .

What are the common technical challenges when using At1g51810 Antibody and how can they be addressed?

Researchers frequently encounter these challenges with plant antibodies:

• Non-specific binding:

  • Optimize blocking conditions (test different blockers: milk, BSA, normal serum)

  • Increase washing stringency and duration

  • Titrate antibody concentration to minimize background

  • Consider pre-adsorption against plant tissue lysates from knockout lines

• Inconsistent band patterns:

  • Test multiple protein extraction methods to ensure complete solubilization

  • Evaluate different reducing agents and their concentrations

  • Consider native vs. denaturing conditions if epitope is conformation-dependent

  • Assess post-translational modifications by treating samples with phosphatases or glycosidases

• Signal variability between replicates:

  • Standardize tissue harvesting conditions (time of day, plant age, growth conditions)

  • Normalize loading using multiple housekeeping proteins

  • Prepare large antibody working stocks to minimize freeze-thaw cycles

  • Implement quantitative analysis with technical and biological replicates

These troubleshooting approaches are essential given that studies have shown many commercially available antibodies may recognize proteins other than their intended targets .

How might emerging antibody development technologies improve future studies of At1g51810?

Recent technological advances promise to enhance antibody quality and specificity:

• Human monoclonal antibody production advances:

  • Isolation of antibody-secreting cells and single-cell sorting enables rapid generation of highly specific monoclonal antibodies

  • These approaches yield greater efficiency than traditional methods like B-cell immortalization or phage display

  • Application to plant proteins could provide superior detection reagents

• AI-driven antibody design:

  • Generative artificial intelligence models can design antibodies de novo with high target specificity

  • Zero-shot design capabilities have been demonstrated for therapeutic targets

  • Computational approaches can predict binding affinity and reduce off-target interactions

  • Such technologies could address specificity issues documented with current antibodies

• Enhanced validation criteria:

  • Implementation of stringent validation frameworks combining orthogonal methods

  • Independent antibody testing with standardized scoring systems

  • Integration of RNA expression correlation analyses

  • These approaches have enabled discovery of previously undetected "missing proteins"

The integration of these technologies represents a promising direction for developing more reliable antibodies for plant research applications, particularly for challenging targets like At1g51810 .